Unleashed Informatics Announce Software Development Collaboration
News May 29, 2006
Leading the collaboration will be Associate Professor Dr Chen Xin, former Manager with the Biomolecular Interaction Network Database (BIND) curation operation at Blueprint Asia based in Singapore.
The collaboration will build upon and extend the well-regarded BIND Interaction Viewer enabling the combination and representation of physical and predicted molecular interactions.
"The Unleashed Informatics team is very excited to engage with top calibre researchers at Zhejiang University to enhance functionality of the BIND Interaction Viewer," said Unleashed Informatics Co-Founder, President and CEO Mr Eric Andrade.
"Of course, we know Dr Chen well through the previous collaboration between Blueprint Asia and the Blueprint Initiative in making BIND the world's definitive interaction database. His research talents are proven and his development vision is persuasive."
Explained Dr Chen, "Our objective here is to produce a graphical analyzer that helps experimental biologists seeking to mine reference networks that consist of reported and predicted interactions relating to utilization of specific nutrients in target crops."
"Results produced with the visualization tool will be made freely available without restriction to researchers worldwide."
"Employing the BIND Interaction Viewer as a foundation for this new graphical analytics tool will save us considerable time and resources."
The enhanced BIND Interaction Viewer will in turn be integrated with the recently announced BINDPlus subscription service from Unleashed Informatics.
BINDPlus is a subscription-based biomolecular database designed to contain physical, associated, and predicted biomolecular interactions spanning genomics, proteomics and metabolomics across all organisms down to an atomic level of detail.
"This new relationship brings together good friends with a solid history of working together in a highly professional manner," says Mr Andrade.
"Within days of initial discussions around the proposed partnership, code had been shared and development progress was being made at an accelerated pace. This lays the groundwork for an ever-deepening, rich and fertile marriage."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.